Kenneth G. Walz
Ken Walz has spent more than 20 years in the biotech and medical device industries in business development and finance roles and has broad experience in the structuring and negotiation of collaborative arrangements, strategy development, and financial planning and analysis. At Popper and Company, he assists early-stage companies in all aspects of financial planning, capital raising, and business development (including deal structuring and negotiation), and tracks the impact of new technologies and mobile medical applications on the life sciences industry.
Prior to co-founding Popper and Company, Mr. Walz was employed as VP, Commercial Development at MDS Proteomics where he led the negotiation of a $50 million research collaboration with a leading biopharmaceutical company. Previously, he managed business planning and analysis for BDGene (a unit of Becton Dickinson & Company), where he played a lead role in the evaluation of alliance candidates, creation of a business development strategy, deal valuation and structuring, and negotiation and closing of agreements.
Mr. Walz earned a Master’s of Science in finance from Loyola College of Maryland and a Bachelor of Arts in economics from the University of Maryland Baltimore County. Mr. Walz currently sits on the board of Fairway Medical Technologies.